Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update
May 04, 2011 08:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - May 4, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces NDA Submitted to the FDA for the Use of CORLUX in Cushing's Syndrome
April 15, 2011 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Apr 15, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11, 2011
March 31, 2011 16:25 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - March 31, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update
March 09, 2011 08:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - March 9, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces Closing of $44.9 Million Underwritten Public Offering of Common Stock
January 26, 2011 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - January 26, 2011) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the...
Corcept Therapeutics Announces Pricing of $39.0 Million Underwritten Public Offering of Common Stock
January 21, 2011 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - January 21, 2011) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the...
Corcept Therapeutics Announces Proposed Public Offering of Common Stock
January 20, 2011 16:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - January 20, 2011) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the...
Corcept Therapeutics Announces Key Secondary Endpoint Was Met in Phase 3 Study of Corlux for Cushing's Syndrome
January 11, 2011 08:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - January 11, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive results on the key secondary endpoint of "global clinical...
Corcept Therapeutics Announces Positive Phase 3 Study Results for CORLUX for the Treatment of Cushing's Syndrome
December 22, 2010 07:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - December 22, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive top-line results from its Phase 3 study of CORLUX for the treatment of...
Corcept Therapeutics to Hold Conference Call Wednesday December 22 at 8:30 am Eastern Time
December 21, 2010 16:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - December 21, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of...